Stifel analyst Paul Matteis reiterated a Buy rating on Biogen (NASDAQ: BIIB) after the aducanumab/Aduhelm label was posted by the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE